{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:14:58Z","timestamp":1793891698696,"version":"4.8.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40265-019-01168-z","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T14:02:58Z","timestamp":1562940178000},"page":"1349-1354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":194,"title":["Volanesorsen: First Global Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Julia","family":"Paik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,12]]},"reference":[{"issue":"23","key":"1168_CR1","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200\u20136.","journal-title":"N Engl J Med"},{"issue":"12","key":"1168_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11883-017-0697-3","volume":"19","author":"NA Rocha","year":"2017","unstructured":"Rocha NA, East C, Zhang J, et al. ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen. Curr Atheroscler Rep. 2017;19(12):62.","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"1168_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s40495-017-0115-0","volume":"3","author":"R Hanssen","year":"2017","unstructured":"Hanssen R, Gouni-Berthold I. Antisense oligonucleotides for the treatment of hypertriglyceridemia and hyperlipoproteinemia. Curr Pharmacol Rep. 2017;3(6):458\u201368.","journal-title":"Curr Pharmacol Rep"},{"key":"1168_CR4","unstructured":"Akcea Therapeutics. Akcea and Ionis announce approval of WAYLIVRA\u00ae (volanesorsen) in the European Union [media release]. 7 May 2019. \nhttp:\/\/www.akceatx.com\n\n."},{"key":"1168_CR5","unstructured":"European Medicines Agency. Volanesorsen: EU summary of product characteristics. 2019. \nhttps:\/\/www.waylivra.eu\/wp-content\/uploads\/2019\/05\/WAYLIVRA-SmPC.pdf\n\n. Accessed 4 July 2019."},{"key":"1168_CR6","unstructured":"Akcea Therapeutics, PTC Therapeutics. Akcea Therapeutics and PTC Therapeutics collaborate to commercialize two rare disease drugs in Latin America [media release]. 2 Aug 2018. \nhttp:\/\/www.akceatx.com\n\n."},{"key":"1168_CR7","unstructured":"European Medicines Agency. Volanesorsen (Waylivra\u00ae): public assessment report; 2019. \nhttps:\/\/www.ema.europa.eu\/\n\n. Accessed 4 July 2019."},{"issue":"11","key":"1168_CR8","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","volume":"112","author":"MJ Graham","year":"2013","unstructured":"Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112(11):1479\u201390.","journal-title":"Circ Res"},{"issue":"3","key":"1168_CR9","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jacl.2017.04.071","volume":"11","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Digenio A, Alexander VJ, et al. The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS) [abstract no. 169]. J Clin Lipidol. 2017;11(3):814\u20135.","journal-title":"J Clin Lipidol"},{"issue":"7","key":"1168_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/14779072.2018.1487290","volume":"16","author":"M Arca","year":"2018","unstructured":"Arca M, Hsieh A, Soran H, et al. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. Expert Rev Cardiovasc Ther. 2018;16(7):537\u201346.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"Suppl","key":"1168_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.atherosclerosissup.2018.04.074","volume":"32","author":"I Gouni-Berthold","year":"2018","unstructured":"Gouni-Berthold I, Alexander VJ, Digenio A, et al. Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial [abstract no. C3-5.04]. Atheroscler Suppl. 2018;32(Suppl):25.","journal-title":"Atheroscler Suppl"},{"issue":"5","key":"1168_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1400283","volume":"373","author":"D Gaudet","year":"2015","unstructured":"Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438\u201347.","journal-title":"N Engl J Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01168-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01168-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01168-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T23:10:43Z","timestamp":1594422643000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01168-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,12]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01168-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,12]]},"assertion":[{"value":"12 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Julia Paik and Sean Duggan are salaried employees of Adis International Ltd\/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}